Investing.comDoubao · 实盘不做把握 7/10不做原因:风险收益比不佳
北京时间·🕒 发布 16:44:46·⟳ 抓取 16:45:13 +27s·⚡ 决策 10-19 21:59:04 +5h13m·8.3 天前
礼来Omvoh(mirikizumab)儿童溃疡性结肠炎III期SHINE-2达主要终点，拟申报标签扩展
正面但极软的适应症扩展读出：仅63人儿科试验、只到计划申报阶段、儿童患者池小(美国约2.6万人)，对市值约1.18万亿美元、由GLP-1驱动的礼来而言收入增量不可感知；市场盘中约-0.2%、盘前-0.6%，完全无正向反应，无事件驱动edge。
📄 原文Investing.com↗ 原文
Lilly reports positive pediatric ulcerative colitis trial data
Tech earnings ahead this week amid AI jitters; oil slips - what’s moving markets INDIANAPOLIS - Eli Lilly and Company (…
不做 Eli Lilly and Company（LLY.US）
消息量级不足以驱动1.18万亿美元市值公司：仅63人儿科III期、计划申报阶段、美国患儿约2.6万人、收入兑现需数年；盘中约-0.24%确认市场无视该软催化，无事件驱动edge，不做多也无做空理由
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Omvoh儿童UC三期阳性是真实但微小的研发里程碑，属计划申报阶段的标签扩展；患者池小、兑现遥远，对1.18万亿美元市值的礼来不具业绩弹性，盘面零反应，不做。
🔎 新鲜度:最早出现 2026-10-19 · 扩散 low · price-in 风险 low ↗
消息传播链
- 消息于UTC 08:44发布，称礼来宣布SHINE-2达主要终点并计划向全球监管提交儿童数据；该文为AI辅助生成的媒体稿，非交易所/公司IR原始链接，未独立取得公司IR原始公告市场反应:美股盘中(09:57 ET)LLY报1254美元、约-0.24%，盘前曾约-0.62%，无正向反应
关键理由
- 事件方向正面但量级不足：儿童UC美国患者仅约2.6万人，距实际批准和销售仍需数年，Omvoh整体收入在礼来数百亿美元体量中占比极小
- 实时行情确认无edge：消息公布约5小时后LLY盘中1254美元、约-0.24%，盘前一度-0.62%，市场未给予任何正向重定价
主要风险
- 本周科技股财报与AI情绪波动及礼来自身财报预期可能主导股价，事件层面信号易被宏观/板块噪音淹没
- 儿童数据仅63例样本，后续监管可能要求补充试验，标签扩展时点与范围存在不确定性
反向证据
- 做多前查反向 · 来源 web · 日期 2026-10-19 · 影响 weakens
未见能反向放大该利好的因素；相反存在样本量小(63例)、监管可能要求补充试验及本周财报/AI情绪主导等抑制因素，进一步削弱做多理由
检索:Omvoh pediatric SHINE-2 safety regulatory delay Lilly; LLY earnings/AI jitters downside 原文 ↗
先例如何影响了这次决策
对本次决策的影响:先例缺口不改变结论：materiality与盘面双重证据已足以AVOID，故未据此设定任何tp/sl
方向:无可用对齐先例；但本决策不依赖先例方向——催化对超大市值主标的缺乏可感知收入增量，且实时盘面已确认零反应
涨幅量级:不足以用先例校准幅度：属巨型药企小型适应症标签扩展，即便同类儿科读出短期通常也仅有低个位数百分点以内、常为零甚至回落的反应
形态:未系统检索到足够首发锚干净的同类礼来儿科标签扩展先例，避免用低质样本编造涨幅
工具执行结果 · 成功 4 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 13 ms
{"result": "search_processed_events:agent query=`eli lilly omvoh pediatric ulcerative colitis shine-2 phase 3 | lly mirikizumab pediatric label expansion shine-2 trial results | omvoh 儿童 溃疡性结肠炎 三期临床`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式没有召回候选，不能据此证明消息首发或不是 - fetch_decision_experience 成功 stock_tools_inprocess · 2 ms
{ - stock_quote 成功 stock_tools HTTP · 298 ms
{ - web_search 成功 doubao_search · 1,619 ms
豆包搜索结果（原始查询:Omvoh mirikizumab 2025 sales revenue Eli Lilly ulcerative colitis；API SearchType:web）
原文全文
展开原文 · 2,194 字
Tech earnings ahead this week amid AI jitters; oil slips - what’s moving markets
INDIANAPOLIS - Eli Lilly and Company (NYSE:LLY) announced today that its drug Omvoh met the primary endpoint in a Phase 3 study for pediatric patients with ulcerative colitis, according to a press release statement.
The SHINE-2 study evaluated Omvoh in 63 patients ages 4 to 17 with moderately to severely active ulcerative colitis. Results showed 81% of patients achieved clinical response at Week 12. Among responders, 50% achieved clinical remission at Week 52, meeting the study’s primary endpoint.
The trial enrolled a population with significant prior treatment experience, with 54% having previously failed biologic therapy. Half of patients entered the study with severe disease activity as measured by the Pediatric Ulcerative Colitis Activity Index.
Key secondary outcomes at one year included 50% of responders achieving corticosteroid-free clinical remission without surgery, 71.2% achieving symptomatic remission, and 53.8% showing endoscopic improvement.
The safety profile in pediatric patients was consistent with that observed in adults, with no new safety signals identified. The most common adverse events were upper respiratory tract infection, injection site reaction, ulcerative colitis, headache, nasopharyngitis and anemia. Through Week 52, four patients experienced a serious adverse event, none considered related to treatment. Two patients discontinued due to ulcerative colitis flare.
Omvoh is currently approved for adults with moderately to severely active ulcerative colitis in 47 countries. The company plans to submit the pediatric data to global regulators to support a potential label expansion.
Ulcerative colitis affects more than 26,000 children and adolescents in the U.S. Pediatric-onset disease is often more extensive and severe than adult-onset disease, with up to half of children becoming dependent on corticosteroids and up to one-third requiring surgery within a year.
The results were presented at United European Gastroenterology Week 2026 in Barcelona.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
INDIANAPOLIS - Eli Lilly and Company (NYSE:LLY) announced today that its drug Omvoh met the primary endpoint in a Phase 3 study for pediatric patients with ulcerative colitis, according to a press release statement.
The SHINE-2 study evaluated Omvoh in 63 patients ages 4 to 17 with moderately to severely active ulcerative colitis. Results showed 81% of patients achieved clinical response at Week 12. Among responders, 50% achieved clinical remission at Week 52, meeting the study’s primary endpoint.
The trial enrolled a population with significant prior treatment experience, with 54% having previously failed biologic therapy. Half of patients entered the study with severe disease activity as measured by the Pediatric Ulcerative Colitis Activity Index.
Key secondary outcomes at one year included 50% of responders achieving corticosteroid-free clinical remission without surgery, 71.2% achieving symptomatic remission, and 53.8% showing endoscopic improvement.
The safety profile in pediatric patients was consistent with that observed in adults, with no new safety signals identified. The most common adverse events were upper respiratory tract infection, injection site reaction, ulcerative colitis, headache, nasopharyngitis and anemia. Through Week 52, four patients experienced a serious adverse event, none considered related to treatment. Two patients discontinued due to ulcerative colitis flare.
Omvoh is currently approved for adults with moderately to severely active ulcerative colitis in 47 countries. The company plans to submit the pediatric data to global regulators to support a potential label expansion.
Ulcerative colitis affects more than 26,000 children and adolescents in the U.S. Pediatric-onset disease is often more extensive and severe than adult-onset disease, with up to half of children becoming dependent on corticosteroids and up to one-third requiring surgery within a year.
The results were presented at United European Gastroenterology Week 2026 in Barcelona.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
6c5038af66· 2026-10-19 21:59 · doubao / doubao-seed-evolving-latest-version · 策略包658c0c1e2ba5当前